The Alzheimer’s disease drug development landscape

The Alzheimer’s disease drug development landscape

Abstract Background Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallma...

Full description

Bibliographic Details
Main Authors: Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, Prisca S. Leferink, Sasja Heetveld, Jeffrey Cummings, Philip Scheltens, Everard G. B. Vijverberg
Format: Article
Language:English
Published: BMC 2021-11-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Drug development, Drug targets
Therapy
Online Access:https://doi.org/10.1186/s13195-021-00927-z

Internet

https://doi.org/10.1186/s13195-021-00927-z

Similar Items